降血脂藥物市場：依藥物類別和地區分類

2025年高降血脂藥物市值估計為157.2億美元，預計到2032年將達到260.8億美元，2025年至2032年的複合年成長率為7.5%。

圖：2025年高降血脂藥物市場佔有率（按地區）

高血脂症是指一系列遺傳性和後天性疾病，會導致血液中膽固醇和三酸甘油酯等脂質水平升高，增加心臟病和中風的風險。高血脂症是一種非常常見的疾病，這導致全球對降血脂藥物的需求不斷成長，這些藥物有助於降低高血脂症和心血管疾病的風險。

市場動態：

高血脂症盛行率上升、久坐生活方式的激增、老年人口的成長、降血脂藥物的需求增加以及新藥的推出是預計將促進全球降血脂藥物市場成長的主要因素。

例如，根據美國中風協會的數據，中風是美國第五大死因和首要殘疾原因。每年，美國有超過79.5萬人中風。其中約61萬人是首次或新發中風。

此外，根據美國心臟協會（AHA）日誌的重新投稿，在歐洲，中風是最常見的死亡原因，也是成人殘疾的主要原因。歐洲中風行動計畫（SAP-E）是一個泛歐洲計劃，旨在製定2030年的實證預防行動和中風服務實施目標。

本研究的主要特點

• 本報告對全球降血脂藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
• 該報告涵蓋了全球降血脂藥物市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球降血脂藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過用於分析全球降血脂藥物市場的各種策略矩陣來促進決策。

目錄：

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 全球高血脂症盛行率不斷上升
  • 治療費用上漲且認知度低
  • 降血脂藥物需求不斷增加
• 影響分析
• 主要亮點
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景

4. 全球降血脂藥物市場-冠狀病毒（COVID-19）大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 2020 年至 2032 年全球降血脂藥物市場（依藥物類別）

• 他汀類藥物
• 膽汁酸螯合劑
• 膽固醇吸收抑制劑
• 纖維酸衍生物
• PCSK9抑制劑
• 組合使用
• 其他

6. 全球降血脂藥物市場（按地區分類），2020-2032 年

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第7章 競爭態勢

• Sanofi SA
• Pfizer Inc.
• Mylan NV
• Amgen Inc.
• Abbvie Inc.
• Merck & Co., Inc.
• Dr. Reddy's Laboratories Ltd.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Daiichi Sankyo Company

第 8 章 章節

• 調查方法
• 關於出版商

Antihyperlipidemic Drugs Market is estimated to be valued at USD 15.72 Bn in 2025 and is expected to reach USD 26.08 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032.

Figure. Antihyperlipidemic Drugs Market Share (%), By Region 2025

Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe an elevated lipid levels, such as cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs across the world, as they help reduce the risk of hyperlipidemia and cardiovascular diseases.

Market Dynamics:

Increasing prevalence of hyperlipidemia, surge in sedentary lifestyle, growing geriatric population, increasing demand for antihyperlipidemic drugs, and introduction of novel drugs are major factors expected to augment the growth of the global antihyperlipidemic drugs market.

For instance, according to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.

Moreover, according to the repost by AHA Journals, in Europe, stroke is the most common cause of death as well as a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of an evidence-based preventive actions and stroke services until 2030.

Key features of the study:

• This report provides in-depth analysis of the global antihyperlipidemic drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global antihyperlipidemic drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global antihyperlipidemic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihyperlipidemic drugs market.

Detailed Segmentation:

• Global Antihyperlipidemic Drugs Market, By Drug Class:
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
• Global Antihyperlipidemic Drugs Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi S.A.
  • Pfizer Inc.
  • Mylan N.V.
  • Amgen Inc.
  • Abbvie Inc.
  • Merck & Co., Inc.
  • Reddy's Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Daiichi Sankyo Company, Limited, among others.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of hyperlipidemia worldwide
  • High cost of treatment and lack of awareness
  • Increasing demand for antihyperlipidemic drugs
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Antihyperlipidemic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Antihyperlipidemic Drugs Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Statins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Bile Acid Sequestrants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cholesterol Absorption Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Fibric Acid Derivatives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• PCSK9 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Combination
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Antihyperlipidemic Drugs Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)

7. Competitive Landscape

• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dr. Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us